ERBB2 and neoplasm: Preclinical and clinical evidence supports combining anti-HER2 treatment with immune checkpoint inhibitors, such as anti-programmed cell death protein 1 (PD-1) antibodies, which may help to overcome intrinsic or acquired resistance by synergistic anti-tumor effect4–9.